White House Covid-19 coordinator of the working group Jeff Zeints said a “break” in Johnson & Johnson’s vaccine administration would not affect national vaccine distribution, despite some officials expecting it to be based on the single vaccine in rural and isolated communities.
“We have enough to continue the current pace of about 3 million photos a day, 200 million photos with [Joe Biden’s] The 100th day of office “, said Zeints in the White House information room.
He later added: “We have enough supplies with Moderna and Pfizer … to move to July 4, which we talked about as a country.”
Six cases of blood clots and low platelet counts in women between the ages of 18 and 48 have led the CDC and the FDA to recommend that states discontinue the vaccine, while the potential links between the vaccine and the syndrome are rarely investigated. More than 6 million doses of Johnson & Johnson vaccine have been administered in the United States.
Officials said there were similarities between the syndrome under investigation and those associated with the AstraZeneca vaccine in Europe and Australia. The AstraZeneca vaccine is not available in the United States. Both Johnson & Johnson and AstraZeneca vaccines share a vaccination technology called a “viral vector.” If a link were established, however, the syndrome would be extremely rare, affecting less than one million vaccinated people.
Health officials also said it was important to discontinue the administration and notify the public about the treatment needed for patients who may be suffering from such clots. The standard treatment for blood clots uses heparin, a blood thinner. In this syndrome, officials said heparin could be “dangerous” and could worsen the syndrome.
“When individuals, especially younger women, go to a doctor with a thrombotic phenomenon, we want to alert doctors to take the history of a recent vaccination,” she said. Dr. Anthony Fauci, Biden’s senior medical adviser. “It would be important.”
The White House had “no involvement” in announcing a “break” in the administration of the Johnson & Johnson vaccine in the United States. Zeints said the administration was “science-led” and would wait for health officials to investigate.
As to whether the potentially rare side effect could increase the vaccine’s hesitation, especially in rural areas where the Johnson & Johnson vaccine was expected to be implemented, Zeints and Fauci said the break represents how seriously the FDA takes patient safety.
“Hesitation in a group of people is a challenge,” Zeints said. “The FDA, acting as they have today, shows that they are indeed the gold standard, and I think that should reassure the American public that they are very diligent.”
Influenza-like side effects in the days immediately following the administration of the vaccine are common side effects and usually resolve within a few days. In all six cases, blood clotting events occurred between six and 13 days after any of the patients received a vaccine.
Symptoms of coagulation syndrome include severe headache, shortness of breath, abdominal and leg pain. People who experience such symptoms about one to three weeks after receiving the vaccine should seek medical attention. People who received the vaccine more than a month ago have a “very low” risk of complications.